Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

SOHO 2026 | Managing patients with CML and additional genetic abnormalities

Jorge Cortes • 10 Sep 2026
SOHO 2026
Chronic Myeloid Leukemia Leukemia

Jorge Cortes, MD, The University of Alabama at Birmingham, Birmingham, AL, discusses a key unresolved question in chronic myeloid leukemia (CML): how to manage patients with additional genetic abnormalities at diagnosis, particularly ASXL1 mutations. He emphasizes the need to better understand optimal treatment strategies and the appropriate timing of transplant to improve outcomes in this patient subset. This interview took place at the 14th Annual Meeting of the Society of Hematologic Oncology (SOHO 2026) in Houston, TX.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Jorge Cortes

Where does the treatment landscape for managing frontline CML currently stand?
1:44
Where does the treatment landscape for managing frontline CML currently stand?
Jorge Cortes • 10 Sep 2026
Consensus recommendations for relapsed/refractory IDH1-mutated AML treatment
1:37
Consensus recommendations for relapsed/refractory IDH1-mutated AML treatment
Jorge Cortes • 12 Jun 2026
QuANTUM-First Q-TWiST analysis supports quizartinib in FLT3-ITD-positive AML
1:53
QuANTUM-First Q-TWiST analysis supports quizartinib in FLT3-ITD-positive AML
Jorge Cortes • 12 Jun 2026
Advances and ongoing challenges in chronic myeloid leukemia management
1:28
Advances and ongoing challenges in chronic myeloid leukemia management
Jorge Cortes • 12 Jun 2026

Related Videos

Insights into the potential of moving towards TKI-sparing strategies in Ph+ ALL
2:27
Insights into the potential of moving towards TKI-sparing strategies in Ph+ ALL
Amin Azem • 10 Sep 2026
How does TKI discontinuation impact patients with Ph+ ALL treated with blinatumomab and ponatinib?
1:30
How does TKI discontinuation impact patients with Ph+ ALL treated with blinatumomab and ponatinib?
Amin Azem • 10 Sep 2026
Major breakthroughs in leukemia treatment: precision therapy and immunotherapy
1:19
Major breakthroughs in leukemia treatment: precision therapy and immunotherapy
Iskra Pusic • 11 Sep 2026
Where does the treatment landscape for managing frontline CML currently stand?
1:44
Where does the treatment landscape for managing frontline CML currently stand?
Jorge Cortes • 10 Sep 2026
The content of VJHemOnc is intended for healthcare professionals